Published in Biomaterials on November 13, 2012
Induced pluripotent stem cells as custom therapeutics for retinal repair: progress and rationale. Exp Eye Res (2014) 0.97
Application of biomaterials to advance induced pluripotent stem cell research and therapy. EMBO J (2015) 0.90
Defining synthetic surfaces for human pluripotent stem cell culture. Cell Regen (Lond) (2013) 0.87
Differentiation of Cardiomyocytes from Human Pluripotent Stem Cells Using Monolayer Culture. Biomark Insights (2015) 0.80
Derivation of transgene-free human induced pluripotent stem cells from human peripheral T cells in defined culture conditions. PLoS One (2014) 0.78
Human-induced pluripotent stem cells generated from intervertebral disc cells improve neurologic functions in spinal cord injury. Stem Cell Res Ther (2015) 0.77
Biomaterial strategies for stem cell maintenance during in vitro expansion. Tissue Eng Part B Rev (2013) 0.76
Modeling Viral Infectious Diseases and Development of Antiviral Therapies Using Human Induced Pluripotent Stem Cell-Derived Systems. Viruses (2015) 0.75
Biomaterials for pluripotent stem cell engineering: From fate determination to vascularization. J Mater Chem B Mater Biol Med (2016) 0.75
Extracellular Matrix-Dependent Generation of Integration- and Xeno-Free iPS Cells Using a Modified mRNA Transfection Method. Stem Cells Int (2016) 0.75
Fibroblast-like cells as an effective feeder for the cultivation and derivation of new lines of human induced pluripotent stem cells. Dokl Biochem Biophys (2016) 0.75
Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med (2010) 10.64
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood (2013) 8.00
Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol (2008) 4.53
PKC-theta knockout mice are protected from fat-induced insulin resistance. J Clin Invest (2004) 3.86
Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood (2011) 3.71
Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J Natl Cancer Inst (2011) 3.51
Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. Nat Genet (2012) 3.43
Regulation of myeloid leukaemia by the cell-fate determinant Musashi. Nature (2010) 3.20
Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood (2010) 3.15
Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood (2006) 2.94
Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. J Clin Oncol (2012) 2.90
Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations. Blood (2009) 2.87
Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase. J Clin Oncol (2009) 2.56
Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. Blood (2012) 2.46
Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood (2013) 2.18
Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Blood (2013) 2.03
Risk-adapted preemptive therapy for cytomegalovirus disease after allogeneic stem cell transplantation: a single-center experience in Korea. Int J Hematol (2005) 2.00
Highly efficient and large-scale generation of functional dopamine neurons from human embryonic stem cells. Proc Natl Acad Sci U S A (2008) 1.97
Previous best responses can be re-achieved by resumption after imatinib discontinuation in patients with chronic myeloid leukemia: implication for intermittent imatinib therapy. Leuk Lymphoma (2009) 1.86
Chronic myeloid leukemia in Asia. Int J Hematol (2008) 1.86
Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors. Blood (2013) 1.83
Robust enhancement of neural differentiation from human ES and iPS cells regardless of their innate difference in differentiation propensity. Stem Cell Rev (2010) 1.77
Functional analysis of various promoters in lentiviral vectors at different stages of in vitro differentiation of mouse embryonic stem cells. Mol Ther (2007) 1.76
Genetic engineering of mouse embryonic stem cells by Nurr1 enhances differentiation and maturation into dopaminergic neurons. Eur J Neurosci (2002) 1.75
Induced pluripotent stem cell models from X-linked adrenoleukodystrophy patients. Ann Neurol (2011) 1.72
Malignant tumor formation after transplantation of short-term cultured bone marrow mesenchymal stem cells in experimental myocardial infarction and diabetic neuropathy. Circ Res (2011) 1.62
Sensitive quantitation of minimal residual disease in chronic myeloid leukemia using nanofluidic digital polymerase chain reaction assay. Leuk Lymphoma (2011) 1.61
Establishment and validation of analytical reference panels for the standardization of quantitative BCR-ABL1 measurements on the international scale. Clin Chem (2013) 1.58
Bone scan images reveal increased osteoblastic function after bortezomib treatment in patients with multiple myeloma. Eur J Haematol (2010) 1.49
Orphan nuclear receptor Nurr1 directly transactivates the promoter activity of the tyrosine hydroxylase gene in a cell-specific manner. J Neurochem (2003) 1.40
Equivalent outcome of autologous stem cell transplantation and reduced intensity conditioning stem cell transplantation in acute myeloid leukemia patients with t(8;21). Acta Haematol (2014) 1.40
Ictal SPECT using an attachable automated injector: clinical usefulness in the prediction of ictal onset zone. Acta Radiol (2009) 1.38
Derivation and characterization of new human embryonic stem cell lines: SNUhES1, SNUhES2, and SNUhES3. Stem Cells (2005) 1.37
Epidemiologic study on survival of chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia patients with BCR-ABL T315I mutation. Blood (2009) 1.36
Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial. J Clin Oncol (2009) 1.35
Efficient induction of oligodendrocytes from human embryonic stem cells. Stem Cells (2006) 1.28
Proteomic analysis of microvesicles derived from human mesenchymal stem cells. J Proteome Res (2011) 1.27
Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA. Blood (2010) 1.26
Validation of recently proposed consensus criteria for thrombotic microangiopathy after allogeneic hematopoietic stem-cell transplantation. Transplantation (2010) 1.23
Reprogramming fibroblasts into induced pluripotent stem cells with Bmi1. Cell Res (2011) 1.20
Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up. Am J Hematol (2014) 1.13
Dual angiogenic and neurotrophic effects of bone marrow-derived endothelial progenitor cells on diabetic neuropathy. Circulation (2009) 1.10
Expression of the c-Met Proteins in Malignant Skin Cancers. Ann Dermatol (2011) 1.09
2009-2010 novel influenza A (H1N1) vaccination coverage in the Republic of Korea. Am J Infect Control (2011) 1.09
Regulation of histone acetyltransferase activity of p300 and PCAF by proto-oncogene protein DEK. FEBS Lett (2006) 1.09
Comprehensive analysis of BCR-ABL transcript types in Korean CML patients using a newly developed multiplex RT-PCR. Transl Res (2006) 1.09
Efficient derivation of functional dopaminergic neurons from human embryonic stem cells on a large scale. Nat Protoc (2008) 1.08
Methods for expansion of human embryonic stem cells. Stem Cells (2005) 1.07
Comparison of allele specific oligonucleotide-polymerase chain reaction and direct sequencing for high throughput screening of ABL kinase domain mutations in chronic myeloid leukemia resistant to imatinib. Haematologica (2006) 1.07
Transparent flexible graphene triboelectric nanogenerators. Adv Mater (2014) 1.06
Avulsion fracture of the calcaneal tuberosity: classification and its characteristics. Clin Orthop Surg (2012) 1.05
Protective effects of hyperoside against carbon tetrachloride-induced liver damage in mice. J Nat Prod (2011) 1.02
Regulation of mouse steroidogenesis by WHISTLE and JMJD1C through histone methylation balance. Nucleic Acids Res (2010) 1.02
Direct reprogramming of rat neural precursor cells and fibroblasts into pluripotent stem cells. PLoS One (2010) 1.02
GarlicESTdb: an online database and mining tool for garlic EST sequences. BMC Plant Biol (2009) 1.01
Allele frequencies of 15 STR loci using AmpF/STR Identifiler kit in a Korean population. Forensic Sci Int (2003) 1.01
Highly pure and expandable PSA-NCAM-positive neural precursors from human ESC and iPSC-derived neural rosettes. PLoS One (2012) 1.01
Multipotent neural stem cells from the adult tegmentum with dopaminergic potential develop essential properties of functional neurons. Stem Cells (2005) 1.00
Chemicals that modulate stem cell differentiation. Proc Natl Acad Sci U S A (2008) 0.99
Chronic 3,4-dihydroxyphenylalanine treatment induces dyskinesia in aphakia mice, a novel genetic model of Parkinson's disease. Neurobiol Dis (2007) 0.99
Allogeneic stem cell transplantation in first complete remission enhances graft-versus-leukemia effect in adults with acute lymphoblastic leukemia: antileukemic activity of chronic graft-versus-host disease. Biol Blood Marrow Transplant (2007) 0.99
Association of HLA alleles with non-Hodgkin's lymphoma in Korean population. Int J Hematol (2008) 0.98
KDM3B is the H3K9 demethylase involved in transcriptional activation of lmo2 in leukemia. Mol Cell Biol (2012) 0.98
Health-related quality of life of bosutinib (SKI-606) in imatinib-resistant or imatinib-intolerant chronic phase chronic myeloid leukemia. Leuk Res (2011) 0.98
High levels of B cell activating factor during the peritransplantation period are associated with a reduced incidence of acute graft-versus-host disease following myeloablative allogeneic stem cell transplantation. Biol Blood Marrow Transplant (2009) 0.97
Analysis of Bcr-Abl kinase domain mutations in Korean chronic myeloid leukaemia patients: poor clinical outcome of P-loop and T315I mutation is disease phase dependent. Hematol Oncol (2009) 0.96
Disease-specific induced pluripotent stem cells: a platform for human disease modeling and drug discovery. Exp Mol Med (2012) 0.96
Complete assignments of 1H and 13C NMR data for 21 naphthalenyl-phenyl-pyrazoline derivatives. Magn Reson Chem (2013) 0.96
Induction of neural stem cell-like cells (NSCLCs) from mouse astrocytes by Bmi1. Biochem Biophys Res Commun (2008) 0.95
Two cases of disseminated mucormycosis in patients following allogeneic bone marrow transplantation. J Korean Med Sci (2002) 0.95
Benzochalcones bearing pyrazoline moieties show anti-colorectal cancer activities and selective inhibitory effects on aurora kinases. Bioorg Med Chem (2013) 0.94
Stem cells as promising therapeutic options for neurological disorders. J Cell Biochem (2013) 0.93
Differential gene expression profiling in human cholangiocarcinoma cells treated with Clonorchis sinensis excretory-secretory products. Parasitol Res (2008) 0.93
Quantitative proteomic analysis of induced pluripotent stem cells derived from a human Huntington's disease patient. Biochem J (2012) 0.93
Comprehensive therapeutic outcomes of frontline imatinib mesylate in newly diagnosed chronic phase chronic myeloid leukemia patients in Korea: feasibility assessment of current ELN recommendation. Int J Hematol (2012) 0.93
Polymorphisms of IL-1B, IL-1RN, IL-2, IL-4, IL-6, IL-10, and IFN-gamma genes in the Korean population. Hum Immunol (2003) 0.93
Dynamic change of T315I BCR-ABL kinase domain mutation in Korean chronic myeloid leukaemia patients during treatment with Abl tyrosine kinase inhibitors. Hematol Oncol (2010) 0.92
Methods for derivation of human embryonic stem cells. Stem Cells (2005) 0.92
Escherichia coli and Klebsiella pneumoniae bacteremia in patients with neutropenic fever: factors associated with extended-spectrum β-lactamase production and its impact on outcome. Ann Hematol (2012) 0.92
Comparative analysis of cell surface proteins in chronic and acute leukemia cell lines. Biochem Biophys Res Commun (2007) 0.92
A direct role of the homeodomain proteins Phox2a/2b in noradrenaline neurotransmitter identity determination. J Neurochem (2002) 0.91
Impact of cytomegalovirus gastrointestinal disease on the clinical outcomes in patients with gastrointestinal graft-versus-host disease in the era of preemptive therapy. Ann Hematol (2012) 0.91
Draft genome sequence of Kocuria rhizophila P7-4. J Bacteriol (2011) 0.91